Dr. Ki Chung, MD
Claim this profilePrisma Health Cancer Institute - Eastside
Expert in Cancer
Expert in Tumors
94 reported clinical trials
192 drugs studied
About Ki Chung, MD
Education:
- Earned an MD from Georgetown University School of Medicine in 1999.
- Graduated from the United States Military Academy at West Point in 1995.
Experience:
- Serves as Professor and Chair of the Department of Medicine at the F. Edward Hebert School of Medicine, Uniformed Services University.
- Held the position of Chief of the Department of Medicine at Brooke Army Medical Center, San Antonio.
- Deployed as Chief of the Intensive Care Unit for the 86th Combat Support Hospital in Baghdad, Iraq, in 2008.
- Served as Director of the Joint Combat Casualty Research Team in Bagram, Afghanistan, in 2012.
- Retired as a Colonel in the U.S. Army and currently the Chief Medical Officer of SeaStar Medical.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Tumors
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Ki Chung, MD is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
Digital Tomosynthesis vs. Standard Mammography
for Breast Cancer Screening
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Recruiting2 awards Phase 34 criteria
More about Ki Chung, MD
Clinical Trial Related5 years of experience running clinical trials · Led 94 trials as a Principal Investigator · 47 Active Clinical TrialsTreatments Ki Chung, MD has experience with
- Pembrolizumab
- Nivolumab
- Carboplatin
- Fluorouracil
- Paclitaxel
- Biospecimen Collection
Breakdown of trials Ki Chung, MD has run
Cancer
Tumors
Colorectal Cancer
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ki Chung, MD specialize in?
Ki Chung, MD focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ki Chung, MD currently recruiting for clinical trials?
Yes, Ki Chung, MD is currently recruiting for 45 clinical trials in Greenville South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Ki Chung, MD has studied deeply?
Yes, Ki Chung, MD has studied treatments such as Pembrolizumab, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Ki Chung, MD?
Apply for one of the trials that Ki Chung, MD is conducting.
What is the office address of Ki Chung, MD?
The office of Ki Chung, MD is located at: Prisma Health Cancer Institute - Eastside, Greenville, South Carolina 29615 United States. This is the address for their practice at the Prisma Health Cancer Institute - Eastside.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.